Alpine Global Management’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Alpine Global Management’s Portfolio DMAAR Stock Details DMAAR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$55K	Buy	500,000 +137,500	+38%	+$14.2K	0.01%	229
2026 Q1	$21.9K	Hold	362,500	–	–	﹤0.01%	211
2025 Q4	$67.9K	Hold	362,500	–	–	0.01%	298
2025 Q3	$78.8K	Buy	+362,500	New	+$67.4K	0.02%	158

Other funds holding DMAAR

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return

Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return

Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return

HCM

Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return

RCM

Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Alpine Global Management's DMAAR Position: Q2 2026 in Review

Alpine Global Management increased its Drugs Made In America Acquisition Corp Rights (DMAAR) stake by 38% in Q2 2026, buying an estimated $14.2K and bringing the position to 500,000 shares worth $55K. The position accounts for 0.01% of the portfolio, ranked #229.

Alpine Global Management first reported a position in DMAAR in Q3 2025 and has held it in 4 quarters since. The position peaked at $78.8K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

Alpine Global Management held 500,000 shares of Drugs Made In America Acquisition Corp Rights worth $55K as of Q2 2026.
Alpine Global Management bought 137,500 Drugs Made In America Acquisition Corp Rights shares in Q2 2026, an estimated $14.2K.
Drugs Made In America Acquisition Corp Rights made up 0.01% of Alpine Global Management's portfolio in Q2 2026, its #229 holding.
Alpine Global Management first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 4 quarters since.
Alpine Global Management's Drugs Made In America Acquisition Corp Rights position peaked at $78.8K in Q3 2025.
28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Alpine Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.